L and J-HZ by L&J Bio for Herpes Zoster (Shingles): Likelihood of Approval

L and J-HZ is under clinical development by L&J Bio and currently in Phase I for Herpes Zoster (Shingles).

Experts say leaked messages present false link between gender-affirming care and cancer

Hundreds of messages from an internal chat board for an international group of transgender health professionals were leaked in a think tank report last week

March 11, 2024

MedUni Vienna scientists identify possible biomarkers for chronic fatigue syndrome

Up to 80,000 people in Austria are estimated to suffer from chronic fatigue syndrome, also known as ME/CFS or myalgic encephalomyelitis/chronic fatigue syndrome.

February 15, 2024

Millions of people became uninsured as Medicaid programs cut coverage, new data show

The national uninsured rate rose from 7.7% to 8.2% earlier this year, a result of states booting millions of Americans from their state Medicaid programs,

August 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.